USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: FOX CHASE CHEMICAL DIVERSITY CENTER, INC
City: DOYLESTOWN
State: PA
Zip+4: 18902-
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $936,255.00 2
SBIR Phase II $1,919,724.00 1
STTR Phase I $600,000.00 2

Award List:

Pathogen-Specific Regulation of Protein Assembly

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Allen B. Reitz
Award Amount: $600,000.00
Abstract:
DESCRIPTION (provided by applicant): One sixth of the world's population has an infectious disease, and new agents involving novel mechanisms less likely to engender resistance are needed if for no other reason than the almost certain emergence of mutant s trains and new pathogens in the future.… More

Riluzole Prodrugs for Melanoma and ALS

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Allen B. Reitz – 215-589-6435
Award Amount: $336,255.00
Abstract:
DESCRIPTION (provided by applicant): Metastatic melanoma has few treatment options, and the current therapeutic standard of care is dacarbazine which is a highly cytotoxic drug with severe side effects including vomiting, headache and hair loss. Treatmentwith dacarbazine has a median… More

DC-SIGN Inhibitors for the Treatment of HIV Infection

Award Year / Program / Phase: 2013 / STTR / Phase I
Agency: HHS
Research Institution: DREXEL UNIVERSITY
Principal Investigator: Allen B. Reitz – 215-589-6435
Award Amount: $300,000.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): DC-SIGN (dendritic cell specific ICAM-3-grabbing non-integrin), a membrane protein of C-type lectin family, is found in high levels on monocyte-derived DCs, some macrophages, and activated B cells. In vivo, DC-SIGN- positive cells were demonstrated in lymph… More

New therapeutics for the treatment of Acinetobactor baumannii infections.

Award Year / Program / Phase: 2013 / STTR / Phase I
Agency: HHS
Research Institution: UNIVERSITY OF PENNSYLVANIA
Principal Investigator: Allen B. Reitz – 215-589-6435
Award Amount: $300,000.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Acinetobacter are strictly aerobic, non-fermentative Gram-negative bacilli that are of major concern in human health, in particular the species Acinetobacter baumannii. They are responsible for clinically important infections that cause a wide variety of maladies… More

Riluzole Prodrugs for Melanoma and ALS

Award Year / Program / Phase: 2013 / SBIR / Phase II
Agency: HHS
Principal Investigator: Allen B. Reitz – 215-589-6435
Award Amount: $1,919,724.00
Abstract:
DESCRIPTION (provided by applicant): We have identified a novel Type IIb prodrug of riluzole, FC-311, which has the potential to revolutionize therapy for the treatment of the devastating condition of metastatic melanoma acting via a novel glutamatergic mechanism of action, and also be useful to… More